31,981 Stryker Corporation $SYK Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB trimmed its stake in Stryker Corporation (NYSE:SYK) by 24.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 99,490 shares of the medical technology company’s stock after selling 31,981 shares during the period. E. Ohman J or Asset Management AB’s holdings in Stryker were worth $27,399,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Pinnacle Bancorp Inc. grew its position in Stryker by 5.2% during the 3rd quarter. Pinnacle Bancorp Inc. now owns 1,017 shares of the medical technology company’s stock valued at $280,000 after purchasing an additional 50 shares during the last quarter. Cypress Wealth Services LLC lifted its stake in Stryker by 6.9% during the 3rd quarter. Cypress Wealth Services LLC now owns 2,254 shares of the medical technology company’s stock valued at $627,000 after acquiring an additional 146 shares during the period. Vest Financial LLC boosted its holdings in Stryker by 12.4% in the third quarter. Vest Financial LLC now owns 1,353 shares of the medical technology company’s stock worth $373,000 after purchasing an additional 149 shares during the last quarter. Eagle Rock Investment Company LLC raised its stake in Stryker by 63.4% during the 3rd quarter. Eagle Rock Investment Company LLC now owns 49,939 shares of the medical technology company’s stock valued at $13,753,000 after buying an additional 19,374 shares during the last quarter. Finally, Arwa LLC raised its stake in Stryker by 4.8% during the 3rd quarter. Arwa LLC now owns 4,104 shares of the medical technology company’s stock valued at $1,159,000 after buying an additional 189 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Wolfe Research cut shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Canaccord Genuity Group lowered their target price on Stryker from $400.00 to $385.00 and set a “buy” rating on the stock in a research report on Friday, September 18th. BTIG Research decreased their price objective on Stryker from $358.00 to $316.00 and set a “buy” rating on the stock in a research note on Monday, October 12th. Citizens Jmp dropped their price target on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Finally, TD Cowen lowered their target price on shares of Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a research note on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $369.00.

Insiders Place Their Bets

In other news, Director Ronda Stryker sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Debra King sold 826 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 over the last quarter. Company insiders own 4.60% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $307.41 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33. The stock has a 50 day moving average of $295.86 and a 200 day moving average of $311.96. The firm has a market cap of $117.91 billion, a PE ratio of 31.86, a PEG ratio of 1.92 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the company earned $3.13 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.